Category - Developments

Developments

Biogen discontinues two Phase 3 trials of aducanumab in Alzheimer’s disease

Biogen (NASDAQ:BIIB) and partner Eisai are discontinuing two global Phase 3 trials to evaluate the efficacy and safety of aducanumab in Alzheimer’s disease (AD). Aducanumab is a monoclonal antibody designed to slow AD...

March 21, 2019

Developments

RTI Surgical enrolls first patient in 3D-printed spinal fusion device study

RTI Surgical (NASDAQ:RTIX) has enrolled the first patient in a clinical trial testing the safety and performance of its Fortilink interbody fusion device. Fortilink is designed to promote spinal fusion after surgery...

March 20, 2019

Developments

Altimmune’s NasoVAX provides 100% seroprotection more than one year after vaccination

Altimmune’s (NASDAQ:ALT) intranasal influenza vaccine, NasoVAX, demonstrated a seroprotective antibody response in all subjects who received the vaccine more than one year ago. The Phase 2a trial of NasoVAX was...

March 20, 2019

Developments

Tiziana Life Sciences submits IND for oral Foralumab

Tiziana Life Sciences (NASDAQ:TLSA, AIM:TILS) submitted an IND to the FDA for its enteric-coated capsules of Foralumab, an anti-CD3 monoclonal antibody. Foralumab, believed to induce an anti-inflammatory response by...

March 20, 2019

Developments

Aptevo Therapeutics initiates Phase 1 trial for anti-inflammatory antibody

Aptevo Therapeutics (NASDAQ:APVO) began dosing subjects in its Phase 1 trial for APVO210, a targeted cytokine immunotherapy. APVO210 is a modified form of the cytokine, IL-10, that suppresses inflammation without...

March 20, 2019

Developments

GeoVax study suggests Ebola vaccine could provide 100% protection with single dose

GeoVax Labs (OTCQB:GOVX) published research showing that a single intramuscular dose of its Ebola vaccine, GEO-EM01, provided 100% protection in rhesus macaques challenged with a lethal dose of Ebola virus. GEO-EM01...

March 20, 2019

Developments

Puma Biotech anti-HER2 breast cancer drug approved in Australia

Puma Biotech (NASDAQ:PBYI) received approval to market neratinib in Australia via its licensing partner, Specialised Therapeutics Asia, who has also submitted an application for regulatory approval in Singapore...

March 19, 2019

Developments

Dare Bioscience publishes positive clinical findings for vaginally-administered tamoxifen

Dare Bioscience’s (NASDAQ:DARE) DARE-VVA1, a proprietary formulation of tamoxifen designed for vaginal delivery, showed significant improvements in reducing vaginal pH and dryness in patients with vulvar and vaginal...

March 19, 2019

Developments

Aerpio Pharma misses primary endpoint in Phase 2b diabetic retinopathy trial

Aerpio Pharmaceuticals (NASDAQ:ARPO) lead candidate, AKB-9778, failed to meet its primary endpoint in its Phase 2b trial for moderate-to-severe non-proliferative diabetic retinopathy (NPDR). Compared to placebo, twice...

March 19, 2019

Developments

Dermira atopic dermatitis drug meets primary endpoint in Phase 2b study

Dermira’s (NASDAQ:DERM) Phase 2b dose-ranging study of lebrikizumab in atopic dermatitis demonstrated that all three doses achieved greater improvements in the Eczema Area and Severity Index score, compared with placebo...

March 19, 2019

Category - Developments

Biogen discontinues two Phase 3 trials of aducanumab in Alzheimer’s disease

RTI Surgical enrolls first patient in 3D-printed spinal fusion device study

Altimmune’s NasoVAX provides 100% seroprotection more than one year after vaccination

Tiziana Life Sciences submits IND for oral Foralumab

Aptevo Therapeutics initiates Phase 1 trial for anti-inflammatory antibody

GeoVax study suggests Ebola vaccine could provide 100% protection with single dose

Puma Biotech anti-HER2 breast cancer drug approved in Australia

Dare Bioscience publishes positive clinical findings for vaginally-administered tamoxifen

Aerpio Pharma misses primary endpoint in Phase 2b diabetic retinopathy trial

Dermira atopic dermatitis drug meets primary endpoint in Phase 2b study

General

More